1 Table of Contents 1 Table of Contents 4 1.1 List of Tables 5 1.2 List of Figures 6 2 Introduction 7 2.1 Ocular Cancer Report Coverage 7 2.2 Retinoblastoma - Overview 7 2.3 Uveal Melanoma - Overview 7 3 Therapeutics Development 8 3.1 Retinoblastoma 8 3.2 Uveal Melanoma 10 4 Therapeutics Assessment 16 4.1 Retinoblastoma 16 4.2 Uveal Melanoma 22 5 Companies Involved in Therapeutics Development 31 5.1 Retinoblastoma 31 5.2 Uveal Melanoma 34 6 Dormant Projects 43 6.1 Retinoblastoma 43 6.2 Uveal Melanoma 43 7 Discontinued Products 44 7.1 Uveal Melanoma 44 8 Product Development Milestones 45 8.1 Retinoblastoma 45 8.2 Uveal Melanoma 49 9 Appendix 62 9.1 Methodology 62 9.2 Coverage 62 9.3 Secondary Research 62 9.4 Primary Research 62 9.5 Expert Panel Validation 62 9.6 Contact Us 62 9.7 Disclaimer 63

Aeglea BioTherapeutics Inc APEIRON Biologics AG Bellicum Pharmaceuticals Inc Bristol-Myers Squibb Co Celldex Therapeutics Inc Cleveland BioLabs Inc Delcath Systems Inc Eli Lilly and Co EyePoint Pharmaceuticals Inc Iconic Therapeutics Inc Immunocore Ltd Innovation Pharmaceuticals Inc Iovance Biotherapeutics Inc Novartis AG Ophthotech Corp PEP-Therapy SAS PepVax Inc Pfizer Inc Plexxikon Inc Polaris Pharmaceuticals Inc Syndax Pharmaceuticals Inc Tesaro Inc VCN Biosciences SL